Juan Carlos Martinez Castrillo

Head. Neurodegenerative Diseases

HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Juan Carlos Martinez Castrillo is the Head of Neurodegenerative Diseases at Hospital Ramón y Cajal in Spain. His research focuses on Parkinson's disease, with recent articles exploring topics such as motor symptoms, dysphagia, and the use of artificial intelligence in treatment strategies. He is actively involved in studies assessing the effectiveness of various therapies and responding to evolving clinical criteria in the field.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (4)

Nélson Costa

University of Minho

PORTUGAL

View details

César Asensio

Universidad Politécnica de Madrid

SPAIN

View details

pilar sanchez

Head of neurodegenerative disease and movement disorders

Hospital Universitario Puerta del Hierro Majadahonda

SPAIN

View details

Raquel Baviera Muñoz

Instituto de Investigación Sanitaria La Fe

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Juan Carlos Martinez Castrillo

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Evolution of the Motor Symptoms in Parkinson Disease under Auditory Stimulation

Evaluation of Free-Living Motor Symptoms in Patients With Parkinson Disease Through Smartwatches: Protocol for Defining Digital Biomarkers

Dysphagia in Parkinson´s disease. A 5-year follow-up study.

Use of the MNCD Classification to Monitor Clinical Stage and Response to Levodopa-Entacapone-Carbidopa Intestinal Gel Infusion in Advanced Parkinson’s Disease

Artificial intelligence for identification of candidates for device-aided therapy in Parkinson's disease: DELIST-PD study.

Effectiveness and safety of levodopa-entacapone-carbidopa infusion in Parkinson disease: A real-world data study.

Concerns with the new biological research criteria for synucleinopathy.

[Inhaled levodopa: from evidence to experience].

Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study.

Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice.

Collaborators (4)

Nélson Costa

César Asensio

pilar sanchez

Raquel Baviera Muñoz

Make your next move.